Is 4-(Dimethyltriazeno)imidazole-5-carboxamide Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 4-(Dimethyltriazeno)imidazole-5-carboxamide? Is 4-(Dimethyltriazeno)imidazole-5-carboxamide safe for nursing mother and child? Does 4-(Dimethyltriazeno)imidazole-5-carboxamide extracts into breast milk? Does 4-(Dimethyltriazeno)imidazole-5-carboxamide has any long term or short term side effects on infants? Can 4-(Dimethyltriazeno)imidazole-5-carboxamide influence milk supply or can 4-(Dimethyltriazeno)imidazole-5-carboxamide decrease milk supply in lactating mothers?

Indicated for treatment of melanoma and Hodgkin disease

Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as 4-(Dimethyltriazeno)imidazole-5-carboxamide.[1] It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence; however, no data are available to determine an appropriate period to withhold breastfeeding. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk. Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.

A woman diagnosed with Hodgkin's lymphoma during the second trimester of pregnancy received 3 rounds of chemotherapy during the third trimester of pregnancy and resumed chemotherapy 4 weeks postpartum. Milk samples were collected 15 to 30 minutes before and after chemotherapy for 16 weeks after restarting. The regimen consisted of doxorubicin 40 mg, bleomycin 16 units, vinblastine 9.6 mg and 4-(Dimethyltriazeno)imidazole-5-carboxamide 600 mg, all given over a 2-hour period every 2 weeks. The microbial population and metabolic profile of her milk were compared to those of 8 healthy women who were not receiving chemotherapy. The breastmilk microbial population in the patient was markedly different from that of the healthy women, with increases in Acinetobacter sp., Xanthomonadacae and Stenotrophomonas sp. and decreases in Bifidobacterium sp. and Eubacterium sp. Marked differences were also found among numerous chemical components in the breastmilk of the treated woman, most notably DHA and inositol were decreased.[2] A telephone follow-up study was conducted on 74 women who received cancer chemotherapy at one center during the second or third trimester of pregnancy to determine if they were successful at breastfeeding postpartum. Only 34% of the women were able to exclusively breastfeed their infants, and 66% of the women reported experiencing breastfeeding difficulties. This was in comparison to a 91% breastfeeding success rate in 22 other mothers diagnosed during pregnancy, but not treated with chemotherapy. Other statistically significant correlations included: 1. mothers with breastfeeding difficulties had an average of 5.5 cycles of chemotherapy compared with 3.8 cycles among mothers who had no difficulties; and 2. mothers with breastfeeding difficulties received their first cycle of chemotherapy on average 3.4 weeks earlier in pregnancy. Of the 6 women who received a 4-(Dimethyltriazeno)imidazole-5-carboxamide-containing regimen, 5 had breastfeeding difficulties.[3]